Science-Backed Immune Booster is Coming in 2022.

Boca Raton, FL -- (ReleaseWire) -- 02/22/2022 -- Enzolytics IPF Immune™, an immune modulator, will be available later this year to American consumers, who, during the pandemic, have been seeking out immunity booster supplements to give themselves a health advantage.

Even before COVID-19, infections, such as the regular flu virus, weakened the immune system. Lifestyle choices, such as an inadequate diet, smoking, and alcohol consumption, also affect the immune system.

"Enzolytics IPF Immune™ strengthens the body's immune system," said Charles S. Cotropia, CEO of Enzolytics, Inc., a Texas biotech company. "COVID-19 made everyone aware and concerned about their immune system."

Since the pandemic started, sales for immune booster supplements have skyrocketed. The global immune health supplements market is projected to grow from $20.18 billion in 2021 to $31.50 billion in 2028.

"Now, consumers have a science-backed immune modulator to keep their bodies operating optimally," he added.

"Our immune modulator helps fortify the immune system against infections," said Harry Zhabilov, the Company CSO. "Enzolytics' research and development team spent more than a decade developing Enzolytics IPF Immune™.

"Enzolytics IPF Immune™ is a liquid nutritional supplement that acts to strengthen the body's natural defenses," Mr. Zhabilov added.

Enzolytics IPF Immune™, which is gluten-free, is taken orally for two consecutive days per week for eight consecutive weeks.

"You can take Enzolytics IPF Immune™ to give your immune system a boost to ward off many infections that your body is confronted with year-round," he added.

For more information, email pr@nutrapr.com or visit enzolytics.com.

About Enzolytics, Inc.
Enzolytics Inc. is a Texas-based biotechnology company that focuses on therapeutics to treat numerous human health medical conditions. In addition to Enzolytics IPF Immune™, which will be on the U.S. market soon, the Company is developing other therapeutics for treating multiple infectious diseases, including monoclonal antibodies for treating COVID-19 and HIV, and anti-cancer therapeutics.

Company Contact:

Enzolytics, Inc.
2000 North Central Expressway
Plano, TX 75074
And

Research Center
Enzolytics, Inc.
Texas A&M University
Institute for Preclinical Studies
College Station, TX 77843-44
SOURCE: Enzolytics, Inc.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm